SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending sharply as investors react to its selection for the U.S. Department of Energy's Genesis Mission, a move seen as significant validation for its AI cloud infrastructure. This development, coupled with an analyst upgrade and renewed optimism in the broader AI sector, is igniting intense community discussions about a potential short squeeze, despite recent volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as its merger with nuclear fusion company TAE Technologies sparks intense community discussion. Many investors view this strategic pivot into energy as a significant catalyst, with talk of a potential short squeeze and a groundbreaking future, while others express strong skepticism, labeling it a speculative "pump and dump" given the nascent stage of fusion technology and the company's trading history. The market is keenly watching how this ambitious energy play unfolds.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is trending strongly following a new "Overweight" rating and a $20 price target from KeyBanc, driving significant bullish sentiment. The community is buzzing with anticipation over an imminent NASA Lunar Terrain Vehicle (LTV) contract award, fueling discussions of a potential short squeeze and long-term upside in the burgeoning space exploration sector. While some express caution regarding current valuations, the dominant conversation centers on LUNR's prospects to lead future lunar missions and its continued growth.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is surging after securing a significant $805 million contract from the Space Development Agency to build 18 missile-tracking satellites, alongside successfully accelerating a U.S. Space Force mission. This landmark award is fueling widespread bullish sentiment, with the community emphasizing the company's strengthening position as a vertically integrated defense-space manufacturer and anticipating further large government contracts within the rapidly expanding space sector.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending sharply lower following its earnings report, despite beating revenue and EPS estimates, driven by significant concerns over declining sales in China and substantial gross margin compression. The community is fiercely debating whether this steep sell-off is an overreaction to a strong global brand or a justified repricing reflecting intense competition and ongoing operational challenges.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as recent developments, including significant funding for its pandemic flu vaccine trial and positive regulatory recommendations for its next-generation COVID vaccine, fuel optimism for its pipeline. Community discussions are active around a potential short squeeze, with many highlighting the company's long-term prospects while others maintain skepticism regarding profitability and ongoing regulatory scrutiny.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

Carnival (CCL) is a top trending stock after reporting robust earnings, achieving investment-grade leverage, and, most notably, reinstating its dividend alongside a share buyback program. The community is buzzing with excitement, viewing this as a significant turnaround and a "game changer" that positions the cruise giant for sustained profitability and attracting long-term investors.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as the community eagerly awaits a "game-changer" partnership announcement, especially with a military contractor, which is widely believed could significantly enhance its role in the expanding AI data training sector. Despite recent market-wide tech sell-offs and debates around the timing of such news, many investors see current price levels as a strategic accumulation zone, driven by conviction in INOD's long-term growth.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace (FLY) is trending as the community eagerly anticipates its enhanced prospects following the strategic acquisition of SciTec, a defense technology firm specializing in missile warning and data analytics. This acquisition, coupled with a new commercial payload agreement for a Moon mission, is seen as a key step towards securing substantial government contracts like the "Golden Dome" initiative and unlocking significant value within the burgeoning space and defense sector.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is generating significant buzz due to the highly anticipated BlueBird 6 satellite launch, with community discussions swirling around its precise timing and the broader implications for ubiquitous satellite-to-device connectivity. Bulls are optimistic about potential government contracts and a looming short squeeze, viewing successful deployment as a validation of the company's long-term vision. However, skepticism persists among some, citing past delays and recent institutional selling, as the market closely watches for execution within the trending space sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the target of unusually large options trading activity on Friday. Stock traders acquired 21,865 call options on the stock. This is...

<ul class="summary-bullets"><li>REGAL is a Phase 3 randomized study testing GPS in AML patients who reached complete remission after a second round of rescue treatment.</li><li>The main goal of the trial is to see whether the treatment helps patients live longer overall.</li><li>Phase 2 of the SLS009 clinical trial found that among AML patients who received exactly one earlier line of treatment, the overall response rate climbed to 58%.</li></ul>SELLAS Life Sciences Group, Inc. (SLS) stock has been drawing continued attention as investors are optimistic about the company’s potential following its positive results in acute myeloid leukemia (AML) treatment.&nbsp;The results from the company’s Phase 2 clinical trial for the investigational drug SLS009 in patients with relapsed or refractory AML with myelodysplastic-related changes (AML-MR) and the Phase 3 REGAL trial, a survival-driven study of galinpepimut-S (GPS), are garnering interest.&nbsp;<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2><a href="https://stocktwits.com/symbol/SLS">SELLAS Life Sciences’ stock</a> inched 0.9% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;A Stocktwits user said if GPS actually works, it will completely change the game, referring to the REGAL trial.<stembedurl>https://stocktwits.com/newTrader9999/message/639398804</stembedurl>Another user said the biggest clear advantage is that combining GPS with SLS009 could lengthen the life cycle of the standard of care to AML patients by many months or even years.<stembedurl>https://stocktwits.com/stockforce123/message/639395388</stembedurl><h2 class="st-heading-2">What Is Phase 3 REGAL Trial</h2>REGAL is a Phase 3 randomized study testing GPS in AML patients who reached complete remission after a second round of rescue treatment (CR2 patients). The main goal of the trial is to see whether the treatment helps patients live longer overall.The final review will begin after 80 events, meaning patient deaths, have taken place, which will help clarify how effective GPS may be for AML patients. At the moment, that number had not yet been met.Phase 2 of the SLS009 clinical trial found that among AML patients who received exactly one earlier line of treatment, the overall response rate climbed to 58%SLS stock has gained over 111% in 2025 and over 150% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-azi-stock-surge-today/cLeJ029REp3">Why Did AZI Stock Surge Over 12% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Senior scientist Zhou Han sets up a quantitative PCR (polymerase chain reaction).

SELLAS Life Sciences Stock Has Doubled This Year – Here’s Why Retail Investors Are Still Bullish 

The results from the company’s Phase 2 clinical trial for the investigational drug SLS009 and the Phase 3 REGAL trial, a survival-driven study of galinpepimut-S (GPS), are garnering interest.

Equity

The results from the company’s Phase 2 clinical trial for the investigational drug SLS009 and the Phase 3 REGAL trial, a survival-driven study of galinpepimut-S (GPS), are garnering interest.


<ul class="summary-bullets"><li>SELLAS’s Phase 2 clinical trial for its investigational drug SLS009 for acute myeloid leukemia showed positive results.&nbsp;</li><li>Across the treated group, the overall response rate (ORR) reached 46%.</li><li>For the cohort with exactly one earlier line of treatment, the ORR climbed to 58%.</li></ul>SELLAS Life Sciences Group, Inc. (SLS) stock came into the spotlight on Monday morning after encouraging results from its Phase 2 clinical trial for its investigational drug SLS009.&nbsp;The trial involved combining SLS009 with azacitidine (AZA) and venetoclax (VEN) in patients with relapsed or refractory acute myeloid leukemia with myelodysplastic-related changes (AML-MR).<h2 class="st-heading-2">What Did Stocktwits Users Say?&nbsp;</h2><a href="https://stocktwits.com/symbol/SLS">SELLAS’ stock</a> traded over 8% higher in Monday’s premarket. On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ the previous day amid ‘high’ message volume.&nbsp;<figure class="image"><img style="aspect-ratio:936/108;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_08_050240_png_2fc0723d0f.webp" alt="SLS’s Sentiment Meter and Message Volume as of 05:00 p.m. ET on Dec. 8, 2025 | Source: Stocktwits" width="936" height="108"><figcaption>SLS’s Sentiment Meter and Message Volume as of 05:00 a.m. ET on Dec. 8, 2025 | Source: Stocktwits</figcaption></figure>A Bullish Stocktwits user said there are many situations where Galinpepimut-S (GPS)and SLS009 can be used alongside venetoclax and azacitidine, creating a powerful multi-drug approach to wipe out AML.<stembedurl>https://stocktwits.com/Juhanialainen/message/638454494</stembedurl>GPS, SELLAS’ lead product candidate, is an immunotherapeutic that targets the Wilms Tumor 1 (WT1) protein.Another user said they always prefer late-stage biotechs to have at least one more solid product or indication in development.<stembedurl>https://stocktwits.com/Sawnchey/message/638460062</stembedurl><h2 class="st-heading-2">Encouraging Response Rates</h2>In the study, 35 evaluable individuals, most with high-risk disease marked by adverse-risk genetics, received SLS009 intravenously at 30 mg twice weekly, alongside AZA/VEN.Across the treated group, the overall response rate (ORR), including complete remission (CR), complete remission with incomplete hematologic recovery (CRi), and morphologic leukemia-free state (MLFS), reached 46%.Patients who had received minimal prior therapy experienced a median overall survival (mOS) of 8.9 months, far exceeding historical survival expectations of roughly 2.5 months in this patient subgroup. For the cohort with exactly one earlier line of treatment, the ORR climbed to 58%.SLS stock has gained over 67% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-ibm-may-want-confluent-3-charts-reveal-ai-play-s-promise/cLIYjkHREll">Why IBM May Want Confluent So Badly: 3 Charts Reveal AI Play's Promise</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Researcher performing microbiology separator for PCR diagnosis test in pathology laboratory. 

SELLAS Life Sciences Draws Retail Buzz On SLS009 Trial Momentum – Stock Soars In Pre-Market

The trial involved combining SLS009 with azacitidine and venetoclax in patients with relapsed or refractory acute myeloid leukemia.

Stock Traders Buy Large Volume of SELLAS Life Sciences Group Call Options (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Stock traders bought 16,073 call options on the stock. This...

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points PR Newswire VANCOUVER, BC, Dec...

Insider Buying: SELLAS Life Sciences Group (NASDAQ:SLS) Director Purchases 63,400 Shares of Stock

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) Director Katherine Bach Kalin purchased 63,400 shares of the firm's stock in a transaction on Wednesday, November 19th. The stock was...

Katherine Bach Kalin Acquires 63,400 Shares of SELLAS Life Sciences Group (NASDAQ:SLS) Stock

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) Director Katherine Bach Kalin acquired 63,400 shares of the firm's stock in a transaction that occurred on Wednesday, November 19th...

SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the target of unusually large options trading on Tuesday. Traders purchased 15,545 call options on the company. This represents an...

SELLAS Life Sciences Group (NASDAQ:SLS) Announces Earnings Results, Beats Expectations By $0.02 EPS

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus...

<ul class="summary-bullets"><li>The company announced the exercise of existing warrants held by an institutional investor.</li><li>The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.&nbsp;</li><li>The transaction is expected to close on or about October 28, the company said.&nbsp; &nbsp;</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 6% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.The warrants were previously issued in March and August 2024, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Group-Announces-Exercise-of-Existing-Warrants-Held-by-a-Current-Institutional-Investor-for-31-Million-in-Gross-Proceeds/default.aspx">said</a>. The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.The new warrants will be exercisable immediately and will expire five years from the date of issuance, the company said.The closing of the translation is expected to occur on or about October 28, it added.Sellas is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapeutics. Its lead product candidate, called GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets a protein present in an array of tumor types.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/SLS"> SLS stock</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user recommended holding the stock, opining that it will now go higher.<stembedurl>https://stocktwits.com/Kevoo/message/633843705</stembedurl>Another dismissed concerns of dilution, terming the warrant exercise a “not that big deal.”<stembedurl>https://stocktwits.com/Risulom/message/633841655</stembedurl> In September, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-stock-in-spotlight-after-institutional-investor-exercises-existing-warrants/chwNYhvRdvv">announced</a> that an institutional investor had exercised the warrants it held to purchase up to 19.69 million shares of the company’s common stock for gross cash proceeds of approximately $23.6 million. The warrants were previously issued in January 2025, the company then said.SLS stock is up by 80% this year and by about 54% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dyne-therapeutics-stock-soars-after-rival-avidity-biosciences-gets-acquired-by-novartis/cLG0X2XR3u7">Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Why Is SELLAS Life Sciences Stock Falling Today?

Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 5% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.

Why Is SELLAS Life Sciences (SLS) Stock Falling Today?

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLS News

SLSSELLAS Life Sciences Group Inc